Clinical Trials & Research

A team of scientists from the USA has recently predicted the driver mutations that may appear in future variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The prediction is based on currently available genetic surveillance data on amino acid mutations present in SARS-CoV-2 variants. A detailed description of the study is currently available on

NEWTON, MA –June 10, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that following a recent Type B meeting with the U.S. Food and Drug Administration (FDA) regarding Acer’s proposed Edsivo™

Scientists are pursuing a new strategy in the protracted fight against the SARS-CoV-2 virus by engineering nanobodies that can neutralize virus variants in two different ways. In lab studies, researchers identified two groups of molecules that were effective against virus variants. Using different mechanisms, nanobodies in each group bypassed mutations and disabled the virus’s ability

New vaccine based on the recombinant spike protein antigen (rS-B.1.351) from Beta (B.1.351) virus lineage highly immunogenic in mice and produced neutralizing antibodies Primates boosted with rS-B.1.351 vaccine induced strong neutralizing immune response to original SARS-CoV-2, Alpha (B.1.1.7) and Beta (B.1.351) variant strains Humans immunized with original NVX-CoV2373 vaccine demonstrated robust antibody responses to original

Understanding cellular metabolism – how a cell uses energy- could be key to treating a wide array of diseases, including vascular diseases and cancer. While many techniques can measure these processes among tens of thousands of cells, researchers have been unable to measure them at the single-cell level. Researchers at the University of Chicago’s Pritzker

93% efficacy against predominantly circulating Variants of Concern and Variants of Interest 91% efficacy in high-risk populations 100% efficacy against variants “not considered Variants of Concern/Interest” All COVID-19 hospitalizations/death occurred in the placebo group Company to host investor conference call today at 8:30 am ET GAITHERSBURG, Md., June 14, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq:

For the third time in nine years, the Affordable Care Act has survived a constitutional challenge at the Supreme Court. In a 7-2 decision, the court ruled that the states and individuals who filed the latest challenge lacked standing to sue. Meanwhile, Democratic lawmakers are looking for ways to expand health benefits as they pull

COVID-19 vaccine candidate efficacy in those 18 to <65 years old was preserved in influenza vaccine recipients Influenza vaccine immunogenicity preserved Study demonstrated no early safety concerns Data available ahead of publication via preprint server, medRxiv  GAITHERSBURG, Md., June 14, 2021 /PRNewswire/ – Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced

Several different causes of aging have been discovered, but the question remains whether there are common underlying mechanisms that determine aging and lifespan. Researchers from the Max Planck Institute for Biology of Aging and the CECAD Cluster of Excellence in Aging research at the University Cologne have now come across folate metabolism in their search

PARIS – June 11, 2021 – Results from Part A of CADENZA, a pivotal Phase 3 double-blind, placebo-controlled study evaluating the safety and efficacy of sutimlimab in people with cold agglutinin disease (CAD) without a recent history of blood transfusion (within the prior six months), will be presented in an oral session at the European Hematology

The vaccination program has commenced in many countries worldwide, which is marked as a significant milestone in curbing the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of the coronavirus disease 2019 (COVID-19) pandemic. These vaccines, which have received emergency authorization from different regulatory bodies around the world, such as the

THOUSAND OAKS, Calif., June 4, 2021 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial. The trial evaluated bemarituzumab plus chemotherapy (mFOLFOX6) versus chemotherapy alone in patients with FGFR2b-positive, HER2-negative frontline advanced gastric or gastroesophageal junction cancers (GEJ). New data includes median overall survival (OS), a secondary endpoint

The term “doomscrolling” describes the act of endlessly scrolling through bad news on social media and reading every worrisome tidbit that pops up, a habit that unfortunately seems to have become common during the COVID-19 pandemic. The biology of our brains may play a role in that. Researchers at Washington University School of Medicine in

KENILWORTH, N.J.–(BUSINESS WIRE) June 9, 2021 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for molnupiravir (MK-4482). Molnupiravir is currently being evaluated in a Phase 3 clinical trial, the MOVe-OUT study, for the treatment of non-hospitalized

The available coronavirus disease 2019 (COVID-19) vaccines generate neutralizing antibodies that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. While the short-term efficacy has been demonstrated, the long-term humoral response in the face of a rapidly mutating pathogen has yet to be characterized in detail. Similarly, individuals

TARRYTOWN, N.Y., June 4, 2021 /PRNewswire/ –  EUA supported by pivotal Phase 3 data showing 1,200 mg dose reduced risk of hospitalization or death by 70% Only antibody therapy currently available in all 50 states, including eight states with high rates of two variants of concern Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and

Researchers found different groups of symptoms persisting after coronavirus disease 2019 (COVID-19), with fatigue and higher IL-6 levels common in women. About 75% of the patients they treated were women, indicating a link between sex hormones and immune response. A large proportion of people who recover from COVID-19 suffer from persistent symptoms even six months

Two-stage design will evaluate vaccine formulations targeting original D.614 virus as well as B.1.351 variant, in diverse geographies with multiple circulating variants A booster study programme will begin in the coming weeks to complement the Phase 3 trial Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021 London

A research group of the Department of Pharmacy and Biotechnology of the University of Bologna analyzed more than one million SARS-CoV-2 genome sequences. This analysis led to the identification of a new variant that, over the past weeks, has been spreading mostly in Mexico but has also been found in Europe. Their paper published in

June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen

Once a virus infects a cell, neighboring cells are likely to become infected by interactions that are dependent on the cell and the virus in question. For example, cell-to-cell spread is facilitated in HIV by viral synapses, which also allow for escape from neutralizing antibodies. Low-level drug inhibitors are able to suppress infection if applied

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 1, 2021– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for the licensure of its mRNA COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes mild to moderate illness in most individuals. However, some people are at a higher risk of developing severe illness due to advanced age, underlying health conditions or immunodeficiencies. Severe COVID-19 is characterized by a hyperactive immune response. In the

NEW YORK–(BUSINESS WIRE) May 24, 2021– Pfizer Inc. (NYSE: PFE) today announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently

A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals. A

Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalization or death in high-risk adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial In vitro data indicate sotrovimab maintains activity against all known variants of concern, including the variant from India Sotrovimab will be available for appropriate

To mark World Vape Day, BAT has today published a comprehensive review of the scientific evidence for vaping products (e-cigarettes), their potential health effects and their role in Tobacco Harm Reduction. This review shows that, over the past decade, the number of people who incorrectly believe vaping is as harmful or more harmful than smoking

ROCKVILLE, Md.–(BUSINESS WIRE)–May 26, 2021– GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at Washington University School of Medicine in St. Louis have dosed the first patient in an investigator-sponsored trial (IST) evaluating uproleselan as a prophylactic agent to reduce gastrointestinal (GI) toxicities associated with high-dose melphalan in autologous hematopoietic cell transplantation (auto-HCT) for multiple myeloma (MM). Dr. Keith Stockerl-Goldstein, M.D., Professor